Magnitude Biosciences, a specialist contract research organisation (CRO) and Durham University spinout, has secured £1.3 million ($1.7 million) in funding to accelerate the commercialisation of VivoScan, its proprietary in vivo high-throughput screening (HTS) platform. VivoScan is unique in providing HTS for drug discovery in a… Read More
CN Bio has introduced two new animal microphysiological system (MPS) models to its contract research services (CRS) that it hopes will enhance translatability in preclinical drug safety and toxicology assessments. Building upon its drug induced liver injury (DILI) assay, the company says the expanded offering enables rapid,… Read More
Dr Kenneth Barr, Senior Vice President, Discovery Services at Syngene International, examines the reality of using AI in drug discovery and its relevance for CROs. In an industry where investments are huge, the time to market is over a decade, and success rates hover around 10%, technological advances that significantly… Read More
A group of former Pfizer employees have created their own businesses based at and supported by Discovery Park, a life sciences community in Kent, UK. The new businesses are all contract research organisations (CROs), namely Biowaived, Matheus Engineering and Particology. Their launch has been supported by… Read More
This paid-for advertorial by Cresset appeared in DDW Volume 25 – Issue 3, Summer 2024. Earlier this year, DDW hosted a webinar, ‘Enhancing collaboration in drug discovery – a biotech perspective’, supported by Cresset. The event emphasised the importance of creating a solid infrastructure within any discovery project to enable… Read More
Earlier this year, Robert S. Langer, Co-founder of Moderna and MIT Professor, made the decision to join the advisory board of Lindus Health, a company labelling itself as an anti-contract research organisation (CRO) and which is dedicated to running faster and more reliable trials for the life sciences industry. Read More
This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers three articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Medicinal cannabis: Why more clinical… Read More
GlobalTrace, the specimen tracking and chain of custody solution from Veridix AI – the technology arm of the Emmes Group – is now being offered to global customers as a standalone service. The CRO expects new markets to be a key part of its growth strategy,… Read More
Traditional drug discovery is time-consuming and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join DDW and FUJIFILM Wako on 24 May 3PM BST to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new… Read More
Traditional drug discovery is time-consuming, and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join FUJIFILM Wako in this webinar to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new proprietary scaffold-hopping method based on AI and chemical… Read More
Traditional drug discovery is time-consuming and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join DDW and FUJIFILM Wako on 24 May 3PM BST to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new… Read More
UK-based Contract Research Organisation (CRO) Gentronix has received a King’s Award for Enterprise after achieving triple-figure revenue growth following rapid expansion in international markets. The toxicology specialist based at Alderley Park recorded total growth of 239% in overseas earning over the past three years. In the same… Read More
Traditional drug discovery is time-consuming and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join DDW and FUJIFILM Wako on 24 May 3PM BST to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new… Read More
Traditional drug discovery is time-consuming, and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join DDW and FUJIFILM Wako on 24 May 3PM BST to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new… Read More
Traditional drug discovery is time-consuming, and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join DDW and FUJIFILM Wako on 24 May 3PM BST to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new… Read More
Join DDW and Revvity Signals for this free event ‘Enhancing collaboration between sponsors and contract partners in drug discovery’. The event will take place on 23 April at 4pm BST / 5pm CEST / 11am EDT / 8am PDT. Most contemporary… Read More
